Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.67 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | FLT1 | P17948 | 2/20 | 0.61 |
| ▸ | FLT4 | P35916 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931087 | 0.93 | PTGS2 (0.71) | PTGS2PTGESKMT2AMEN1LMNA | |
| SCHEMBL3292237 | 0.92 | PTGS2 (0.69) | PTGS2PTGESKMT2AMEN1LMNA | |
| SCHEMBL9176266 | 0.91 | PTGS2 (0.78) | PTGS2PTGESKMT2AFLT1FLT4 | |
| SCHEMBL5931288 | 0.91 | FLT1 (0.71) | PTGS2KMT2AMEN1LMNAFLT1 | |
| SCHEMBL174010 | 0.87 | FLT1 (0.77) | PTGS2KMT2AMEN1LMNAFLT1 | |
| SCHEMBL15679406 | 0.86 | FLT1 (0.61) | PTGS2KMT2AMEN1LMNAFLT1 | |
| SCHEMBL7278965 | 0.86 | P4HTM (0.65) | PTGS2KMT2AMEN1LMNAFLT1 | |
| SCHEMBL7774521 | 0.85 | LMNA (0.74) | PTGS2PTGESKMT2AMEN1LMNA | |
| SCHEMBL7647250 | 0.85 | LMNA (0.74) | PTGS2PTGESKMT2AMEN1LMNA | |
| SCHEMBL29011132 | 0.85 | FLT1 (0.74) | PTGS2KMT2AMEN1LMNAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0542556-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1995-07-19 | — | — | EP | claimed |
| US-5314859-A | Thermosensitive recording material | OJI PAPER CO., LTD. (JP) | 1994-05-24 | — | — | US | claimed |
| EP-0542556-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1993-05-19 | — | — | EP | claimed |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-9212134-B2 | Inhibitors of viral entry into mammalian cells | MICROBIOTIX, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130331456-A1 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | MICROBIOTIX, INC. | 2013-12-12 | — | — | US | disclosed |
| WO-2013118805-A1 | 3-SUBSTITUTED PROLINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2013-08-15 | — | — | WO | disclosed |
| EP-2616073-A2 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | Microbiotix, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120196854-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2012037119-A2 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | MICROBIOTIX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-0503856-A1 | Thermosensitive recording material | OJI PAPER COMPANY LIMITED (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331456-A1 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | HAVCR2, PIGS, ZC3HAV1 | PTGS2 3726/4885PTGES 4023/4885USP2 2469/4885 |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, HBG1 | PTGS2 606/4885PTGES 319/4885USP2 3325/4885 |
| US-20120196854-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND | CYP2C18, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 | PTGS2 3664/4885PTGES 4470/4885USP2 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.